Eli Lilly to expand pain pipeline with $1bn SiteOne buyout
Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big…
Central Nervous System
-
-
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in…
-
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla (donanemab) to treat…
-
AbbVie expands siRNA push with $335m ADARx deal
AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering…
-
Viralgen and Trogenix to progress gene therapy for glioblastoma
Contract development and manufacturing organisation (CDMO) Viralgen has partnered biotech company Trogenix to accelerate the development of a recombinant adeno-associated…
-
Eli Lilly signs $415m deal for Alchemab’s ALS therapy
UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy…
-
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with…
-
Biohaven secures $600m financing as it awaits FDA prodrug decision
Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with non-dilutive capital…
-
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a…
-
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute…
